JSJohn Paul Seenan

John Paul Seenan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John Paul Seenan has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In Vitro Effects of Twelve Food Additives on Gut Microbiome and Its Fibre Fermentation Capacity in Adults with Crohn’s Disease in Remission and Healthy Controls

    by Hanoof Alessa, Molly Elizabeth Quinn, Linah Alhomidan, Cameron Ross, Stefanos Kainadas, Emily Brownson, Jonathan MacDonald, John Paul Seenan, Ben Nichols, Athanasios Koutsos, et al.

    Background/Objectives: Animal studies have shown that food additives may adversely affect the gut microbiome. However, the effect of food additives on the microbiome in adults with Crohn’s disease (CD) remains less explored. This study investigated the impact of food additives on gut microbiome and fibre fermentation capacity in adults with CD and healthy controls (HCs) using in vitro faecal fermentations. Methods: Faeces from 6 HCs and 6 patients with CD in clinical remission (Harvey Bradshaw Index < 5) were used for in vitro fermentation of a fibre mix with one of 12 food additives (calcium propionate, carboxymethylcellulose, carrageenan kappa, cinnamaldehyde, maltodextrin, polysorbate-80, potassium sorbate, sodium benzoate, sodium sulphite, titanium dioxide, turmeric, and xanthan gum). Short-chain fatty acids (SCFAs) were measured using gas chromatography, the microbiome was profiled with 16S rRNA amplicon sequencing and total bacterial load was measured with qPCR. Results: Maltodextrin increased acetate production in both groups. In HCs, turmeric increased acetate and butyrate production, sodium sulphite reduced acetate production, and maltodextrin reduced butyrate production. Microbiome Shannon α-diversity increased with titanium dioxide (both groups), and with carrageenan kappa only in patients with CD. In both groups, the addition of maltodextrin and polysorbate-80 induced significant shifts in microbiome structure (β-diversity). Significant shifts were seen with maltodextrin (HC: R2 = 6.8%, p = 0.001; CD: R2 = 5.1%, p = 0.004) and sodium sulphite (HC: R2 = 6.9%, p = 0.001). Maltodextrin significantly decreased the estimated absolute abundance of Escherichia–Shigella in patients CD; sodium benzoate, potassium sorbate, and calcium propionate did so in HCs. Faecalibacterium decreased in the presence of polysorbate-80 in the HC and CD groups, as well as in the presence of maltodextrin in the CD group. Total bacterial load decreased with polysorbate-80, potassium sorbate, maltodextrin and calcium propionate in both groups. Xanthan gum decreased total bacterial load in HCs. Conclusion: Certain food additives significantly affected fibre fermentation capacity and microbiome structure, with only modest differences observed according to participants’ health status.


  • Open Access

    The Changing Landscape in Patients With Crohn's Disease

    by Solomon Ong, John Paul Seenan

  • Open Access

    Machine learning approach to dissect the clinical heterogeneity of IBD-associated fatigue

    by Cher S Chuah, Rebecca Hall, Robert J Whelan, Peter D Cartlidge, Beatriz Gros, Eva Iglesias-Flores, Nikita Parkash, Ray K Boyapati, Clara Ramos-Belinchon, Solomon Ong, et al.

    Extreme fatigue is a clinical symptom that affects >50% of individuals with Inflammatory Bowel Disease (IBD), with a similar prevalence across many common immune-mediated inflammatory diseases (IMIDs). Despite its ubiquity, human scientific studies have yet to explain the mechanistic basis of this pervasive and complex symptom. One fundamental reason for this, is our inability to account for the clinical heterogeneity of fatigue with its multifactorial nature. We present the conceptual machine learning (ML) framework to dissect the complex nature of fatigue using one of the largest prospectively captured, real-world patient-reported outcome (PROs) on wellbeing from three contemporaneous cohorts (2020-present), totalling 2,970 responses from 2,290 participants across the UK and internationally, including non-IBD controls with 100 lines of clinical metadata. We systematically defined the (1) threshold of fatigue as our primary outcome (≥10/14 fatigue days) to build our ML approach, (2) utilised routinely available clinical data that can be used at a population-level analysis, (3) employed seven different ML methods with external validation in 3 different cohorts in UK, Spain and Australia (n=252), (4) employed Shapley Additive Explanations (SHAP) analysis to break down the clinical heterogeneity to allow the examination of clinical predictive factors at an individual level; and finally (5), investigate whether there are distinct clusters of fatigue patients. We found that ML models performed comparably (AUC/C-index ∼0.7) on external validation with SHAP analysis showing interpretable, individualised fatigue drivers and five distinct fatigue phenotypes, including a subgroup of young males with significantly lower fatigue burden. Our data therefore provides the ML ‘roadmap’ to predict and deconstruct fatigue in IBD and potentially also more widely in IMIDs, enabling patient-level dissection beyond symptom-based classification with the ability to integrate deep molecular data. This is a step towards future clinical-scientific AI models with the immediate clinical application to stratify patients to human experimental studies to better understand the dominant mechanisms that drive fatigue at an individual level.


  • Drug-induced liver injury with autoimmune features secondary to infliximab for ulcerative colitis

    by Ailsa Gemmell, Andrew Fraser, Karin Oien, John Paul Seenan

    We present a patient with a drug-induced liver injury with autoimmune features as a result of infliximab therapy for ulcerative colitis. This is a rare but serious side effect in patients receiving this treatment which clinicians should consider in the event of liver function test derangement.


  • Republished: Acute interstitial nephritis secondary to vedolizumab

    by Nicholas Simpson, John Paul Seenan, Rajan Patel, David Kipgen

    We present a patient with an acute kidney injury thought secondary to acute interstitial nephritis as a result of vedolizumab maintenance therapy for Crohn’s disease. This appears to be a rare but serious side effect in patients receiving this treatment which clinicians should consider in the event of renal dysfunction.

  • Acute interstitial nephritis secondary to vedolizumab

    by Nicholas Simpson, John Paul Seenan, Rajan Patel, David Kipgen

    We present a patient with an acute kidney injury thought secondary to acute interstitial nephritis as a result of vedolizumab maintenance therapy for Crohn’s disease. This appears to be a rare but serious side effect in patients receiving this treatment which clinicians should consider in the event of renal dysfunction.


  • Open Access

    Pathogenesis of Musculoskeletal Deficits in Children and Adults with Inflammatory Bowel Disease

    by Lewis Steell, Stuart R. Gray, Richard K. Russell, Jonathan MacDonald, John Paul Seenan, Sze Choong Wong, Daniel R. Gaya

    Musculoskeletal deficits are among the most commonly reported extra-intestinal manifestations and complications of inflammatory bowel disease (IBD), especially in those with Crohn’s disease. The adverse effects of IBD on bone and muscle are multifactorial, including the direct effects of underlying inflammatory disease processes, nutritional deficits, and therapeutic effects. These factors also indirectly impact bone and muscle by interfering with regulatory pathways. Resultantly, individuals with IBD are at increased risk of osteoporosis and sarcopenia and associated musculoskeletal morbidity. In paediatric IBD, these factors may contribute to suboptimal bone and muscle accrual. This review evaluates the main pathogenic factors associated with musculoskeletal deficits in children and adults with IBD and summarises the current literature and understanding of the musculoskeletal phenotype in these patients.


  • Open Access

    Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn’s disease—new insights into dietary disease triggers

    by Michael Logan, Konstantinos Gkikas, Vaios Svolos, Ben Nichols, Simon Milling, Daniel R Gaya, John Paul Seenan, Jonathan Macdonald, Richard Hansen, Umer Z Ijaz, et al.

    Summary: Background: Exclusive enteral nutrition (EEN) is an effective treatment for Crohn's disease.Aims: To investigate the hypothesis that ingredients of EEN formulas are unlikely to initiate a disease flare and that their dietary elimination is not essential for disease amelioration.Methods: We performed compositional analysis of EEN formulas with evidence of efficacy in management of active Crohn's disease. Macronutrient content was compared against the dietary reference values (DRV), the UK National Diet and Nutrition Survey (NDNS) and intake of Crohn's disease children. Food additives were cross‐referenced against the FAO/WHO database.Results: Sixty‐one formulas were identified with variable composition (carbohydrates [22.8%‐89.3%], protein [7.8%‐30.1%], fat [0%‐52.5%]). Maltodextrin, milk protein and vegetable/plant oils were the commonest macronutrient sources. Their n‐6:n‐3 fatty acid ratio varied from 0.25 to 46.5. 56 food additives were identified (median per formula: 11). All formulas were lactose‐free, gluten‐free, and 82% lacked fibre. The commonest food additives were emulsifiers, stabilisers, antioxidants, acidity regulators and thickeners. Food additives, implicated in Crohn's disease aetiology, were present in formulas (modified starches [100%], carrageenan [22%], carboxymethyl cellulose [13%] and polysorbate 80 [5%]). Remission rates did not differ between EEN formulas with and without those food additives. Analysis including only formulas from randomised controlled trials (RCTs) retained in the latest Cochrane meta‐analysis produced similar findings. EEN formulas contained less energy from saturated fat than NDNS intake.Conclusion: We have identified food ingredients which are present in EEN formulas that are effective in Crohn's disease and challenge perceptions that these ingredients might be harmful.


  • Open Access

    DOP02 The dose-dependent effect of enteral nutrition on faecal microbial metabolites of healthy volunteers

    by V Svolos, K Gkikas, V Rizou, E Christina, P Kapranos, J Kleingunnewiek, J P Seenan, J Macdonald, D R Gaya, R Hansen, et al.

    Treatment with exclusive enteral nutrition (EEN) offers a nutritional therapy paradigm in Crohn’s disease, with the extensive modulation of gut microbiome being its proposed mechanism of action (1). Recent studies propose variable clinical efficacy for 85% EN (Cheat EN/CEN), 50% EN (Partial EN/PEN) and 20% EN (maintenance EN/MEN), and a dose-dependent effect of EN use in CD (2–5). Therefore, this study aims to investigate the dose-dependent effect of 100%, 85%, 50%, and 20% EN on faecal microbial metabolites; and to investigate if this effect can be used as a compliance marker for EEN. Healthy adults followed EEN, CEN, PEN or MEN diet for 7 days. Fresh faecal samples were collected before and after each dietary intervention Dietary assessment was performed throughout the intervention using estimated weight food diaries. Faecal pH, water content, Bristol Stool Chart Score, short-chain fatty acids and hydrogen sulphide were measured. A total of 122 faecal samples were collected from 61 subjects. The Mean(SEM) EN intake for the four groups was EEN: 100(0), CEN: 85.6(0.5), PEN: 50.1(0.4), MEN: 19.9(0.2) % of total energy intake. The baseline levels of all faecal sample measures were no different between the four groups. Faecal water content, propionic acid and Bristol Stool Chart Score significantly decreased only during EEN (all p≤0.03). Faecal pH significantly increased during EEN, CEN and PEN (all p < 0.001), but not during MEN (p = 0.728). Faecal pH post-intervention was highest for EEN, followed by CEN and PEN [Mean(SEM), EEN: 8.2(0.1); CEN: 7.8(0.2); PEN: 7.3(0.1), all pairwise p ≤ 0.002]. The faecal concentration of hydrogen sulphide, acetic and butyric acid significantly decreased following both EEN and CEN groups (all p ≤ 0.009). The concentration of acetic acid post-EEN was significantly lower than the concentration post CEN [Mean(SEM), EEN: 173(10); CEN: 261(24) μmol/g, p = 0.001]. Hydrogen sulphide and butyric acid concentrations post EEN and post CEN were unchanged (p = 0.337, p = 0.141). EEN extensively modulates faecal microbial metabolites and CEN induces similar effects. PEN induces variable effects and further analysis should investigate if variation in responses reflects differences in the non-EN food intake of the participants (50%). MEN had no effect on faecal microbial metabolites. Further analysis including high-throughput deep sequencing techniques will provide additional information about the dose-dependent effect of EN regimen on gut microbiome composition. References 1. Quince et al., Am J Gastroenterol, 110:1718–1729. 2. Logan et al., Aliment Pharmacol Ther, 2019;50:664–674. 3. Gupta et al., IBD, 2013;19:1374–1378. 4. Duncan et al., BMC Gastroenterol, 2014;14:50. 5. Lee et al., IBD, 2015;21:1786–1793.